2型糖尿病的微小RNA生物标志物:基于荟萃分析与通路建模的证据合成
本研究综合了微小RNA与2型糖尿病关联研究及通路描绘研究,从156项对照研究中鉴定出404个差异表达微小RNA,其中60个在人类2型糖尿病中持续且显著失调;经通路影响分析,16个微小RNA符合生物标志物筛选标准并给出验证优先级顺序。
要点
- 从156项对照研究(合计样本量>15,000)中鉴定出404个差异表达微小RNA,仅60个在人类2型糖尿病中持续且显著失调。
- 敏感性分析显示58个微小RNA稳健;亚组分析未发现多个组织中均持续且显著失调的微小RNA。
- 16个微小RNA符合生物标志物筛选标准,验证优先级首位为miR-29a-3p,其次为miR-221-3p、miR-126-3p等。
核心结论
- 16个微小RNA符合生物标志物筛选标准,按显著性和相关性排序的验证优先级为:miR-29a-3p、miR-221-3p、miR-126-3p、miR-26a-5p、miR-503-5p、miR-100-5p、miR-101-3p、mIR-103a-3p、miR-122-5p、miR-199a-3p、miR-30b-5p、miR-130a-3p、miR-143-3p、miR-145-5p、miR-19a-3p和miR-311-3p。
研究设计与样本
- 从PubMed、ScienceDirect和Web of Science检索符合条件的2型糖尿病微小RNA表达谱对照研究。
- 整合miRTarBase、TransmiR、miRecords、TargetScanHuman、KEGG和Retraction Watch数据库数据,进行微小RNA调控的2型糖尿病通路描绘研究。
- 共纳入156项对照表达谱研究,合计样本量>15,000;鉴定出1966项通路描绘研究,包含3290个微小RNA-靶标相互作用,结合KEGG通路产生225条微小RNA调控通路。
- 注册号:PROSPERO CRD42017081659。
主要发现
- 在156项对照研究中鉴定出404个差异表达微小RNA,仅60个在人类2型糖尿病中持续且显著失调。
- 亚组分析未发现多个组织中均持续且显著失调的微小RNA。
- 敏感性分析显示58个微小RNA稳健。
- 影响分析发现,从广泛荟萃分析中鉴定的16个失调微小RNA在增强的KEGG 2型糖尿病通路中具有统计学显著富集。
关键数值与推荐
- 16个微小RNA符合生物标志物筛选标准,验证优先级顺序为:miR-29a-3p、miR-221-3p、miR-126-3p、miR-26a-5p、miR-503-5p、miR-100-5p、miR-101-3p、mIR-103a-3p、miR-122-5p、miR-199a-3p、miR-30b-5p、miR-130a-3p、miR-143-3p、miR-145-5p、miR-19a-3p和miR-311-3p。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: MicroRNAs are being sought as biomarkers for the early identification of type 2 diabetes. This study aimed to synthesise the evidence from microRNA-type 2 diabetes association studies and microRNA-regulated type 2 diabetes pathway delineation studies that met stringent quality criteria to identify and validate microRNAs of both statistical and biological significance as type 2 diabetes biomarkers. METHODS: Eligible controlled studies on microRNA expression profiling of type 2 diabetes were retrieved from PubMed, ScienceDirect and Web of Science. MicroRNA-regulated type 2 diabetes pathway delineation studies were conducted by integrating and cross-verifying the data from miRTarBase, TransmiR, miRecords, TargetScanHuman, the Kyoto Encyclopedia of Genes and Genomes (KEGG) and the Retraction Watch database. Before meta-analysis, quality assessment was performed according to the corresponding reporting guidelines for evidence-based medicine. To select the most statistically significant microRNAs, we conducted extensive meta-analyses according to the latest methodology. Subgroup and sensitivity analyses were carried out to further examine the microRNA candidates for their tissue specificity and blood fraction specificity and the robustness of the evidence. Signalling pathway impact analysis of dysregulated microRNAs identified from meta-analyses was performed to select biologically significant microRNAs that were enriched in our newly built microRNA-regulated pathways. RESULTS: Of the 404 differentially expressed microRNAs identified in the 156 controlled profiling studies with a combined sample size of >15,000, only 60 were both consistently and significantly dysregulated in human type 2 diabetes. No microRNAs were both consistently and significantly dysregulated in multiple tissues according to subgroup analyses. In total, 58 microRNAs were found to be robust in sensitivity analyses. A total of 1966 pathway delineation studies were identified, including 3290 microRNA-target interactions, which were further combined with KEGG pathways, producing 225 microRNA-regulated pathways. Impact analysis found that 16 dysregulated microRNAs identified from extensive meta-analyses were statistically significantly enriched in the augmented KEGG type 2 diabetes pathway. CONCLUSIONS/INTERPRETATION: Sixteen microRNAs met the criteria for biomarker selection. In terms of both significance and relevance, the order of priority for verification of these microRNAs is as follows: miR-29a-3p, miR-221-3p, miR-126-3p, miR-26a-5p, miR-503-5p, miR-100-5p, miR-101-3p, mIR-103a-3p, miR-122-5p, miR-199a-3p, miR-30b-5p, miR-130a-3p, miR-143-3p, miR-145-5p, miR-19a-3p and miR-311-3p. REGISTRATION: PROSPERO registration number CRD42017081659.
引用
- Zhu H, Leung SW. MicroRNA biomarkers of type 2 diabetes: evidence synthesis from meta-analyses and pathway modelling. Diabetologia. 2022. PMID: 36269347. doi:10.1007/s00125-022-05809-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。